M
mlchance
Guest
When Dr. Lester Crawford was nominated to head the FDA, we were concerned because he had not openly opposed the FDA’s approval of RU-486, the dangerous abortion drug that was fast- tracked in a manner generally reserved for drugs to treat “life- threatening” conditions. Now, last I checked, pregnancy rarely constitutes a life-threatening condition. At the same time, the fast-tracking of RU-486 meant that the approval process bypassed standard procedures and data requirements. We were concerned that this would take a deadly toll on the lives of women. Unfortunately, we were correct. Monday, as Dr. Crawford was confirmed, Danco Laboratories, the exclusive manufacturer of Mifeprex, one of the drugs used in the RU-486 two-day cocktail, announced that it will be including updated safety information on Mifeprex labeling.
Danco’s press statement acknowledged the deaths of five women from septic shock after taking RU-486 - four Americans and one Canadian. However, Danco did not mention the following RU-486-related deaths: an American who died from a ruptured ectopic pregnancy; the death of a Swedish teenager who bled to death; the death of one British woman from hemorrhagic shock; and, the death of another Briton whose precise cause of death is unknown. The foreign deaths employed an RU-486 regimen similar to that used in the U.S. Both domestic and foreign deaths appear to total at least nine. Danco’s own admission should prompt Dr. Crawford to make a priority of reviewing the FDA’s approval of RU-486.
Danco’s press statement acknowledged the deaths of five women from septic shock after taking RU-486 - four Americans and one Canadian. However, Danco did not mention the following RU-486-related deaths: an American who died from a ruptured ectopic pregnancy; the death of a Swedish teenager who bled to death; the death of one British woman from hemorrhagic shock; and, the death of another Briton whose precise cause of death is unknown. The foreign deaths employed an RU-486 regimen similar to that used in the U.S. Both domestic and foreign deaths appear to total at least nine. Danco’s own admission should prompt Dr. Crawford to make a priority of reviewing the FDA’s approval of RU-486.